Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  0.05 0.81% 6.20 698,806 11:34:30
Bid Price Offer Price High Price Low Price Open Price
5.68 6.00 6.20 6.00 6.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.12 -8.94 -3.25 18
Last Trade Time Trade Type Trade Size Trade Price Currency
11:33:42 O 100,000 5.80 GBX

Immupharma (IMM) Latest News

More Immupharma News
Immupharma Investors    Immupharma Takeover Rumours

Immupharma (IMM) Discussions and Chat

Immupharma (IMM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Immupharma trades in real-time

Immupharma (IMM) Top Chat Posts

Immupharma Daily Update: Immupharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 6.15p.
Immupharma Plc has a 4 week average price of 5p and a 12 week average price of 5p.
The 1 year high share price is 10.60p while the 1 year low share price is currently 4.80p.
There are currently 284,984,933 shares in issue and the average daily traded volume is 2,028,949 shares. The market capitalisation of Immupharma Plc is £17,669,065.85.
lord loads of lolly: Eva Perón - maybe drop the running commentary now. Chances are, if the FDA approves another phase 3 trial, share price will rise (temporarily at least). Equally, if it doesn't, share price will fall. Simples.
eva_1989: what baffled me about IMM are two things: 1. Why there are no news from other products 2. Why Tim or Management not buying further ? No de-ramp here and even if i'm it doesn't matter to share price but there was pin drop silence about IMM other products Map hardly £20M something big is going to happen me think if FDA approved and i thin they have no reason to say no then this should fly really want to free my money here but double should be fine ;)
sicilian_kan: There are a number of expenses in the past year that will not repeat. Management etc costs will be down £1m this year, another near £1m of convertible loans were repaid last year, then we have the PK study costs that will not be incurred this year. Plus there are Lanstead monies due. The key here for IMM is to get FDA approval of the P3 study post PK study, which will boost the share price, which will divert costs onto Avion who are funding the P3, and which will increase the revenues from the Lanstead deals. How quickly they can do this - and whether they can get through without raising monies in the immediate future - is not known though.
mudbath: The IMM share price moves as if on a snakes and ladders board where the trades(or dice)that should determine its ascent or descent apparently having no influence. Nevertheless, it is a great stock from which to extract a daily margin, as the MMs seem happy to part with the shares in the morning at 5.75p only to seek their return at 6p or above, after lunch.
pwhite73: COLSMITH - "why don't they hold the stock and sell into the rise?" They cannot do that because wherever CLNs are involved the funder can only make money when selling at prices below what PIs have bought at. This is also true for 99% of placings. If the funder holds onto the stock until it rises then they are competing with PIs and everybody else who is trading for a profit. The funder gets out at prices where you would incur a loss. That's how the system works. IMM have every financial incentive to release news that boosts the share price so Lanstead get out at higher price for their placing stock which in turn enriches IMM.
pwhite73: Contrary to the RNS statements I don't believe IMM are still involved in the development of Lupuzor and this is why its going to be a major success. Avion are bearing the entire cost of the international Phase III study. They have also received strong indications from the FDA that the drug will be approved perhaps even before the end of the Phase III trial. They don't want IMM fking things up like last time. This is why I believe they are keeping the PK data close to their chests despite the agreement stating all clinical data will be shared. IMM have been relegated to funding the directors wages by a death spiral Share Agreement. This is what is wiping out all share gains. Shareholders have to await general news Avion offers to IMM. That's my take on what's happening and in the long run its good for PIs who are prepared to bottom drawer the share.
nobbygnome: There is a joint steering committee (see RNS link below) so it would be extraordinary if IMM didn't know the results. I have been involved personally in these sorts of collaborations and the data would always be shared!
pwhite73: You want premiums paid on higher share prices not lower share prices.
pwhite73: tomboyb - That's because Lanstead are trashing the shares everyday as part of the Share Agreement (RNS 20/12/2021). Lanstead has invested £2.2 million in the company and can recover their investment by selling £91,667 worth of shares every month for a 24 month period. That's why no rises can be held onto at the moment. Avion are funding the P3 trials for up to $25 million. This money is nothing to do with IMM they see none of it. The plan is when the P3 trials start and other commercial partnerships are announced the current market cap and share price will be a distant memory and the Lanstead monthly sales of £91,667 which is peanuts will have no effect on the share price. However in the absence of any positive news the Lanstead sells everyday are dragging the price down as there are no buyers at the moment until further news is announced.
eva_1989: Lord - you'll understand me over the period of time. But for now I'm in no mood to promote or to encourage someone to invest in IMM. Let's admit - IMM not going anywhere for atleast 2-3 months. 5P doubt but 6P deft coming... Harley - Even though I doesn't own you but here is my last few purchases... see that do* IMM - hate it. I wanted to sell my Gold fund for IMM but I've now held on to that thoughts.. 6P i will think and it's 10000% coming!!! 30/07/2021 Immupharma Plc Code: IMM.LN Buy 9,999.0000 152742701 £844.09 30/07/2021 Immupharma Plc Code: IMM.LN Buy 99,999.0000 152742196 £8,069.52 30/07/2021 Immupharma Plc Code: IMM.LN Buy 86,661.0000 152732542 £7,000.80 29/07/2021 AXA Framlington Gbl Tech Z Acc Code: 03TL.LN Buy 47.1010 152453315 £333.00 29/07/2021 BlackRock Gold & General D Acc Code: FMP2.LN Buy 2,565.9820 152453312 £35,000.00 29/07/2021 BlackRock Gold & General D Acc Code: FMP2.LN Buy 2,565.9830 152424697 £35,000.00
Immupharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220629 12:11:48